FDA
-
-
-
-
-
-
-
UroGen reports 64.5% three-year response rate for ZUSDURI bladder cancer drug
-
-
-
-
-
-
-
UroGen launches ZUSDURI as revenue rises 21% in 2025
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
-
-
-
-
-
-
-
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

